Catridecacog is a recombinant FXIII subunit‐A molecule evaluated for clotting factor replacement therapy in congenital FXIII deficiency. Coagulation Factor XIII A-Subunit (Recombinant), also known as catridecacog, is a recombinant form of the Factor XIII-A2 homodimer composed of two factor XIII (FXIII) A-subunits.
- Mechanism
- Curator reviewed
Pharmacologically active on Coagulation factor XIII A chain and Coagulation factor XIII B chain
- Primary indication
- For routine prophylaxis of bleeding in patients with congenital factor XIII A-Subunit deficiency.Curator reviewed · 1 structured indication
- First approval
- Canada, 2012 · United States, 2013 · European Union, 2016
- Also known as
- Coagulation Factor XIII A-Subunit (recombinant) · Factor XIII A-Subunit (Recombinant) · Recombinant Coagulation Factor XIII
- Brand names
Resolves to
Clinical / RWD
Targets
What you can answer from here — as of June 15, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Catridecacog, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account